Skip to Main Content

A Phase I/II Study of VTX-801 in Adult Patients With Wilson's Disease (GATEWAY)

Conditions

Diseases of the Endocrine System | Genetics - Adult

Phase I-II

What is the purpose of this trial?

The objectives of this clinical trial are to assess, for up to 5 years, the safety, tolerability and pharmacological activity of a single ascending doses of VTX-801, a gene therapy, administered intravenously (IV) to adult patients with Wilson's Disease prior to and following background WD therapy withdrawal.

  • Trial with
    Vivet Therapeutics, SAS
  • Start Date
    08/01/2021
  • End Date
    07/31/2023

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

  • Last Updated
    09/23/2021
  • Study HIC
    #2000028887